Literature DB >> 11132269

Use of hydroxyapatite to fill cavities after excision of benign bone tumours. Clinical results.

T Yamamoto1, T Onga, T Marui, K Mizuno.   

Abstract

We treated 75 patients with benign bone tumours by curettage and filling the defect with calcium hydroxyapatite (HA). There were 28 women and 47 men with a mean age of 27.7 years (3 to 80). The mean follow-up was for 41.3 months. Postoperative radiological assessment revealed that the implanted HA was well incorporated into the surrounding host bone in all patients. Two patients suffered fractures in the postoperative period. Two patients complained of pain associated with HA in the soft tissues, but this diminished within six months. No patient had local pain at the final follow-up. Recurrence of the tumour was seen in three cases. Histopathological study of the implanted area showed removal of the HA by histiocytes and multinucleated giant cells, and the formation of much appositional bone. We conclude that HA is an excellent bone-graft substitute in surgery for benign bone tumours.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11132269     DOI: 10.1302/0301-620x.82b8.11194

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  20 in total

1.  Use of purified beta-tricalcium phosphate for filling defects after curettage of benign bone tumours.

Authors:  M Hirata; H Murata; H Takeshita; T Sakabe; Y Tsuji; T Kubo
Journal:  Int Orthop       Date:  2006-05-31       Impact factor: 3.075

2.  Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors.

Authors:  Kazutaka Koto; Hiroaki Murata; Yasushi Sawai; Eishi Ashihara; Motoyuki Horii; Toshikazu Kubo
Journal:  Oncol Lett       Date:  2017-06-08       Impact factor: 2.967

3.  Biphasic bone substitute and fibrin sealant for treatment of benign bone tumours and tumour-like lesions.

Authors:  Stephan Reppenhagen; Johannes C Reichert; Lars Rackwitz; Maximilian Rudert; Peter Raab; Guy Daculsi; Ulrich Nöth
Journal:  Int Orthop       Date:  2011-05-28       Impact factor: 3.075

4.  Vancomycin-loaded nano-hydroxyapatite pellets to treat MRSA-induced chronic osteomyelitis with bone defect in rabbits.

Authors:  Ji-Le Jiang; Yun-Fei Li; Tao-Lin Fang; Jian Zhou; Xi-Lei Li; Yi-Chao Wang; Jian Dong
Journal:  Inflamm Res       Date:  2011-12-11       Impact factor: 4.575

5.  Effect of hydroxyapatite on bone integration in a rabbit tibial defect model.

Authors:  Myung-Jin Lee; Sung-Keun Sohn; Kyung-Taek Kim; Chul-Hong Kim; Hee-Bae Ahn; Mee-Sook Rho; Min-Ho Jeong; Sang-Kyu Sun
Journal:  Clin Orthop Surg       Date:  2010-05-04

6.  Osteogenic protein-1 for long bone nonunion: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-04-01

7.  Major bone defect treatment with an osteoconductive bone substitute.

Authors:  Stefania Paderni; S Terzi; L Amendola
Journal:  Chir Organi Mov       Date:  2009-06-16

8.  High strength bioactive glass-ceramic scaffolds for bone regeneration.

Authors:  Chiara Vitale-Brovarone; Francesco Baino; Enrica Verné
Journal:  J Mater Sci Mater Med       Date:  2008-10-21       Impact factor: 3.896

9.  Comparison of outcomes and safety of using hydroxyapatite granules as a substitute for autograft in cervical cages for anterior cervical discectomy and interbody fusion.

Authors:  Hosein Mashhadinezhad; Fariborz Samini; Reza Zare
Journal:  Arch Bone Jt Surg       Date:  2014-03-15

10.  Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects.

Authors:  K C Saikia; T D Bhattacharya; S K Bhuyan; D J Talukdar; S P Saikia; P Jitesh
Journal:  Indian J Orthop       Date:  2008-04       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.